Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apixaban for paediatric venous thromboembolism: cautious optimism.

The Lancet. Haematology·2026
Same author

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Atherosclerosis·2026
Same author

Harmonization of measurement units: mission impossible or ethical imperative?

Clinical chemistry and laboratory medicine·2026
Same author

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Prevalence, predictors, and clinical impact of vitamin D deficiency on 12-month outcomes in hip fracture patients.

Journal of endocrinological investigation·2026
Same author

Prospective comparison of viscoelastic coagulation monitor (VCM) and rotational thromboelastometry (ROTEM) in the assessment of cirrhosis coagulopathy.

Thrombosis research·2026
Same journal

Correction to: May Measurement Month 2017: screening for hypertension in Nigeria-Sub-Saharan Africa.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Optimizing protected PCI strategies in the setting of chronic kidney disease and advanced coronary artery disease: a clinical case-based discussion.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Patient selection for complex, high-risk indicated percutaneous coronary intervention procedures: an overview.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Protected percutaneous coronary intervention of complex distal left main disease with Impella CP™ support.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Impella™-protected PCI in a post-CABG patient with advanced biventricular dysfunction and mitral regurgitation.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Contemporary evidence in protected percutaneous coronary intervention: a case-based review.

European heart journal supplements : journal of the European Society of Cardiology·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Focus on lipoprotein(a).

Marta Biolo1, Camilla Portinari1, Camilla Goffi1

  • 1Clinica Medica 1, Department of Medicine, University Hospital-Padua, Via Giustiniani 2, Padua 35128, Italy.

European Heart Journal Supplements : Journal of the European Society of Cardiology
|May 8, 2026
PubMed
Summary
This summary is machine-generated.

Elevated Lipoprotein(a) [Lp(a)] is a key cardiovascular risk factor. Current management focuses on lowering LDL cholesterol, while novel therapies targeting Lp(a) show promising reductions.

Keywords:
ASOCardiovascular diseaseLipoprotein(a)siRNA

Related Experiment Videos

Last Updated: May 9, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Lipoprotein(a) [Lp(a)] is a significant, independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis.
  • Elevated Lp(a) affects approximately 20% of the population, with levels primarily determined by genetic variations in the LPA gene.

Purpose of the Study:

  • To review the role of Lp(a) as a cardiovascular risk factor.
  • To discuss current management strategies for elevated Lp(a).
  • To explore emerging therapeutic approaches for Lp(a) reduction.

Main Methods:

  • Review of current clinical guidelines and therapeutic strategies for managing elevated Lp(a).
  • Examination of the genetic basis of Lp(a) regulation.
  • Assessment of novel Lp(a)-lowering therapies in development.

Main Results:

  • Lp(a) possesses enhanced atherogenic, pro-inflammatory, and prothrombotic properties compared to LDL.
  • Current guidelines recommend intensive LDL cholesterol lowering to manage residual risk from Lp(a).
  • Lipoprotein apheresis offers substantial Lp(a) reduction but has limited applicability.

Conclusions:

  • Innovative therapies, including gene silencing and assembly inhibitors, demonstrate significant Lp(a) reduction (up to 80-90%).
  • These novel approaches offer potential for causal therapeutic strategies pending cardiovascular outcome trial results.